^
    Back
    Association details:
    Biomarker:CXCL12 expression
    Cancer:Glioblastoma
    Drug:olaptesed pegol (NOX-A12) (CXCL12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Potential predictive biomarker for response to radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial.

    Published date:
    05/25/2023
    Excerpt:
    Biomarker analyses revealed that a higher frequency of CXCL12 expressing endothelial and glioma cells (EG12 score) significantly correlated with PFS (r=0.87; p=0.005) in patients treated with RT and NOX-A12...We show superior clinical efficacy of RT and NOX-A12 in patients with high frequency of CXCL12 expressing endothelial and glioma cells, suggesting the use of the EG12 score as a novel predictive biomarker for CXCL12-directed therapies in GBM.
    DOI:
    10.1200/JCO.2023.41.16_suppl.2048
    Trial ID:
    GLORIA